RayzeBio, Inc.

31 articles about RayzeBio, Inc.

• RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/13/2023

  RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today reported financial results for the third quarter ended September 30, 2023 and provided an update on key corporate initiatives.

• RayzeBio to Participate in Upcoming Investor Conferences in November 2023

  11/6/2023

  RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company’s management team will participate in the following investor conferences in November 2023.

• RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

  11/1/2023

  RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced the appointment of Tim Van Hauwermeiren to its board of directors.

• FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs

  10/24/2023

  RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, announced the FDA has selected RYZ101 into the inaugural Chemistry, Manufacturing, and Controls Development and Readiness Pilot program.

• RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress

  10/18/2023

  RayzeBio, Inc. today announced that it will be presenting interim safety and efficacy data from the Phase 1b portion of the ACTION-1 Trial for RYZ101 (Ac225 DOTATATE) at the upcoming European Society of Medical Oncology (ESMO) Congress, being held in Madrid between 20-24 October 2023.

• RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  9/19/2023

  RayzeBio, Inc. (Nasdaq: RYZB) today announced the closing of its previously announced upsized $358 million initial public offering (IPO) of 19,869,240 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 2,591,640 additional shares from RayzeBio, at a price to the public of $18.00 per share.

• 

  RayzeBio’s $311M, Neumora’s $250M IPOs Among Biotech’s Largest This Year

  9/15/2023

  The two biotech companies announced initial public offering pricing Thursday, respectively, with shares beginning trading Friday and valued at more than $560 million cumulatively.
• 

  Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

  9/15/2023

  In the largest biotech Series C financing so far this year, Generate:Biomedicines raised $273 million, while Neumora and RayzeBio announced IPO pricing valued at more than $560 million combined.

• RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering

  9/14/2023

  RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the pricing of its upsized $311 million initial public offering of 17,277,600 shares of common stock at a price to the public of $18.00 per share.

• RayzeBio Appoints Christy Oliger to its Board of Directors

  8/29/2023

  RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Christy Oliger to its board of directors.

• RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting

  6/22/2023

  RayzeBio, Inc. today announced that the Company will be presenting dosimetry data for its lead clinical program, RYZ101 (Ac225 DOTATATE) at the annual meeting of Society of Nuclear Medicine and Molecular Imaging (SNMMI), being held from June 24 - 27, 2023 at McCormick Place, Chicago, Illinois.

• RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

  5/31/2023

  RayzeBio, Inc. today announced that the first patient has been dosed in the Phase 3 trial of RYZ101 in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior Lutetium-177 labelled somatostatin analogue therapy.

• RayzeBio to Present at Upcoming Medical Conferences

  5/22/2023

  RayzeBio, Inc. today announced that the Company will be presenting data for its lead clinical program, RYZ101 (Ac225 DOTATATE) at two upcoming medical conferences as well as presentations on preclinical programs.

• PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical Therapeutic Development Candidate

  3/22/2023

  PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination of the second targeted peptide radiopharmaceutical clinical development candidate arising from their strategic partnership with RayzeBio, Inc., (“RayzeBio”), a privately held California-based targeted radiopharmaceutical company developing innovative cancer drugs.

• RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer

  3/21/2023

  RayzeBio, Inc. today announced the nomination of a first-in-class novel peptide drug candidate against GPC3. As GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, it has a compelling profile for targeted cancer therapy.

• RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors

  3/20/2023

  RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced the completion of enrollment in the Phase 1b portion of the ACTION-1 Phase 1b/3 trial of RYZ101 in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who have progressed on Lutetium-177 labelled somatostatin analogue therapy.

• RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)

  1/4/2023

  RayzeBio, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to the Company’s lead clinical asset, RYZ101, which uses 225 Ac-DOTATATE to treat somatostatin receptor-positive (SSTR+) tumors.

• RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023

  1/4/2023

  RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.

• RayzeBio Appoints Industry Veteran Rich Heyman, Ph.D. as Chairman of Board of Directors

  12/7/2022

  RayzeBio, Inc. appointed Rich Heyman, Ph.D. as chair of the board of directors. Dr. Heyman is an accomplished biotechnology veteran with over 25 years of operational experience.

• RayzeBio to Present at Upcoming Investor Conferences in November 2022

  11/14/2022

  RayzeBio, Inc. announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the following investor conferences in November 2022: Jefferies London Healthcare Conference: Presentation on Wednesday, November 16 at 12:20 p.m. GMT in London, England.